“The FDA approval of RHOFADE exemplifies Allergan’s commitment to continuing to address unmet patient needs through innovation in medical dermatology,” said David Nicholson, chief R&D officer of Allergan plc. “We know persistent facial erythema associated with rosacea is a challenge for patients and physicians and having options can help in treating the disease. RHOFADE is the first and only alpha adrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults. The FDA approval of RHOFADE represents a new prescription treatment that can effectively help physicians and their patients manage this condition.”
You May Also Like: Is It Acne or Something Else?
Rosacea affects nearly 16 million Americans and can appear as a “flushing or sunburn that won’t go away.”
Allergan also said that what makes this cream different is that one daily application can reduce the redness associated with rosacea through 12 hours.
RHOFADE will be available in May in the U.S.